Neurocrine Gets $10M From Venrock
Luke Timmerman12/17/09
Neurocrine Biosciences, the San Diego-based biotech company, said today it raised about $10 million through a stock offering to Venrock Associates. The company (NASDAQ: NBIX) said it sold 4.78 million shares of Neurocrine at $2.09 apiece to Venrock. That’s about an 8 percent discount to the market price of $2.27 at yesterday’s close.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
